Phase 2 Study Adding Pracinostat to a Hypomethylating Agent (HMA) in Patients With MDS Who Failed to Respond to Single Agent HMA

NCT01993641 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

45

Enrollment

INDUSTRY

Sponsor class

Conditions

Myelodysplastic Syndrome
MDS

Interventions

DRUG: pracinostat
DRUG: Azacitidine
DRUG: Decitabine

Sponsor

Helsinn Healthcare SA